Identification of FDA-approved drugs that increase mevalonate kinase in hyper IgD syndrome

被引:1
|
作者
Politiek, Frouwkje A. [1 ,2 ]
Turkenburg, Marjolein [1 ]
Koster, Janet [1 ]
Ofman, Rob [1 ]
Waterham, Hans R. [1 ,2 ,3 ,4 ]
机构
[1] Amsterdam Univ Med Ctr, Acad Med Ctr, Dept Lab Med, Lab Genet Metab Dis, Amsterdam, Netherlands
[2] Amsterdam Gastroenterol Endocrinol & Metab, Amsterdam, Netherlands
[3] Amsterdam Reprod & Dev, Amsterdam, Netherlands
[4] Amsterdam Univ Med Ctr, Acad Med Ctr, Lab Genet Metab Dis F0 222, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
cholesterol biosynthesis; clobetasol propionate; glucocorticoids; mevalonate kinase deficiency; systemic autoinflammatory diseases; HYPERIMMUNOGLOBULINEMIA-D; CHOLESTEROL; DEFICIENCY; MUTATIONS; PHENOTYPE; SERIES; BIOSYNTHESIS; GENOTYPE; SPECTRUM; CELLS;
D O I
10.1002/jimd.12698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mevalonate kinase deficiency (MKD) is an autoinflammatory metabolic disorder caused by bi-allelic loss-of-function variants in the MVK gene, resulting in decreased activity of the encoded mevalonate kinase (MK). Clinical presentation ranges from the severe early-lethal mevalonic aciduria to the milder hyper-IgD syndrome (MKD-HIDS), and is in the majority of patients associated with recurrent inflammatory episodes with often unclear cause. Previous studies with MKD-HIDS patient cells indicated that increased temperature, as caused by fever during an inflammatory episode, lowers the residual MK activity, which causes a temporary shortage of non-sterol isoprenoids that promotes the further development of inflammation. Because an increase of the residual MK activity is expected to make MKD-HIDS patients less sensitive to developing inflammatory episodes, we established a cell-based screen that can be used to identify compounds and/or therapeutic targets that promote this increase. Using a reporter HeLa cell line that stably expresses the most common MKD-HIDS variant, MK-V377I, C-terminally tagged with bioluminescent NanoLuc luciferase (nLuc), we screened the Prestwick Chemical Library (R), which includes 1280 FDA-approved compounds. Multiple compounds increased MK-V377I-nLuc bioluminescence, including steroids (i.e., glucocorticoids, estrogens, and progestogens), statins and antineoplastic drugs. The glucocorticoids increased MK-V377I-nLuc bioluminescence through glucocorticoid receptor signaling. Subsequent studies in MKD-HIDS patient cells showed that the potent glucocorticoid clobetasol propionate increases gene transcription of MVK and other genes regulated by the transcription factor sterol regulatory element-binding protein 2 (SREBP-2). Our results suggest that increasing the flux through the isoprenoid biosynthesis pathway by targeting the glucocorticoid receptor or SREBP-2 could be a potential therapeutic strategy in MKD-HIDS.
引用
收藏
页码:302 / 316
页数:15
相关论文
共 50 条
  • [11] An analysis of FDA-approved drugs for oncology
    Kinch, Michael S.
    DRUG DISCOVERY TODAY, 2014, 19 (12) : 1831 - 1835
  • [12] Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
    Wu, Peng
    Nielsen, Thomas E.
    Clausen, Mads H.
    DRUG DISCOVERY TODAY, 2016, 21 (01) : 5 - 10
  • [13] Identification of FDA-approved Drugs that Computationally Bind to MDM2
    Warner, Wayne A.
    Sanchez, Ricardo
    Dawoodian, Alex
    Li, Esther
    Momand, Jamil
    CHEMICAL BIOLOGY & DRUG DESIGN, 2012, 80 (04) : 631 - 637
  • [14] Identification of FDA-approved drugs that computationally bind to MDM2.
    Warner, W. A.
    Sanchez, R.
    Dawoodian, A.
    Esther, L.
    Momand, J.
    MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [15] Identification of FDA-approved drugs that target hepatitis B virus transcription
    van de Klundert, M. A. A.
    Zaaijer, H. L.
    Kootstra, N. A.
    JOURNAL OF VIRAL HEPATITIS, 2016, 23 (03) : 191 - 201
  • [16] "Hyper-IgD syndrome" or "mevalonate kinase deficiency": an old syndrome needing a new name?
    Celsi, Fulvio
    Tommasini, Alberto
    Crovella, Sergio
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (03) : 423 - 424
  • [17] “Hyper-IgD syndrome” or “mevalonate kinase deficiency”: an old syndrome needing a new name?
    Fulvio Celsi
    Alberto Tommasini
    Sergio Crovella
    Rheumatology International, 2014, 34 : 423 - 424
  • [18] A review on synthesis of FDA-approved antipsychotic drugs
    Rani, Anjali
    Aslam, Mohd
    Pandey, Garima
    Pant, Bhaskara Nand
    TETRAHEDRON, 2023, 138
  • [19] An analysis of FDA-approved drugs for pain and anesthesia
    Kinch, Michael S.
    DRUG DISCOVERY TODAY, 2015, 20 (01) : 3 - 6
  • [20] An analysis of FDA-approved drugs for metabolic diseases
    Kinch, Michael S.
    Umlauf, Sheila
    Plummer, Mark
    DRUG DISCOVERY TODAY, 2015, 20 (06) : 648 - 651